|
| Trial number | Phase | Chemotherapy | Stage of the disease | Number of patients (estimated) |
|
| NCT00127920 (AV53206s) | II | Carboplatin + paclitaxel + bevacizumab | Newly diagnosed stage III/IV | 20 |
| NCT00296816 (TEACO) | II | Oxaliplatin + docetaxel + bevacizumab | Newly diagnosed stage IB-IV | 145 |
| NCT00511992 (AVF3953) | II | Paclitaxel + cisplatin + bevacizumab followed by bevacizumab | Newly diagnosed stage II-III | 20 |
| NCT00588237 (06-064) | II | Paclitaxel + cisplatin + bevacizumab | Initial treatment of optimal stage II or III (adjuvant) | 42 |
| NCT00267696 (2005CO073) | II | Gemcitabine + carboplatin + bevacizumab | Platinum-sensitive recurrent | 45 |
| NCT00698451 (CR015094) | II | Carboplatin + liposomal doxorubicin + bevacizumab | Platinum-sensitive recurrent | 54 |
| NCT00418093 (04-356) | II | Oxaliplatin + gemcitabine + bevacizumab | Platinum-sensitive recurrent | 40 |
| NCT00868192 (08-0508) | II | Pemetrexed + bevacizumab | Recurrent having failed platinum- and taxane-based regimens | 25 |
| NCT00504257 (MCC-14920, MCC-105366c) | II | Docetaxel + bevacizumab | Platinum-resistant recurrent | 44 |
| NCT00744718 (2008-000878-20, S-20080033) | II | Carboplatin + bevacizumab | Platinum-resistant recurrent | 30 |
| NCT00846612 (06-948, AVF3910s) | II | Liposomal doxorubicin + bevacizumab | Platinum-resistant recurrent | 48 |
| NCT00856180 (08-148) | II | Cyclophosphamide + bevacizumab | Platinum-resistant recurrent | 20 |
| NCT00407563 (ALSSOPR0501) | II | Abraxane (protein-bound paclitaxel ) + bevacizumab | Platinum-resistant recurrent | 48 |
| NCT00937560 (MO22225) | II | Carboplatin + paclitaxel + bevacizumab | Previously untreated, but initial surgery | 188 |
| NCT00583622 (2007-0368) | II | Gemcitabine + docetaxel + melphalan + carboplatin + bevacizumab | Second or later complete remission, or untreated or refractory relapse to platinum treatment or lack of response to salvage treatment | 40 |
| NCT00483782 (ICON7) | III | Carboplatin + paclitaxel ± bevacizumab | Newly diagnosed | 1520 |
| NCT00262847 (GOG218) | III | Carboplatin + paclitaxel versus carboplatin + paclitaxel + bevacizumab ± maintenance bevacizumab | Newly diagnosed, previously untreated stage III or IV | 2000 |
| NCT00565851 (GOG213) | III | Carboplatin + paclitaxel ± bevacizumab followed by bevacizumab and secondary cytoreduction surgery | Platinum-sensitive recurrent | 660 |
| NCT00434642 (OCEANS, AVF4095g) | III | Carboplatin + gemcitabine ± bevacizumab | Platinum-sensitive recurrent | 487 |
| NCT00652119 (2007-0223) | N/A | Carboplatin + paclitaxel + bevacizumab | Newly diagnosed stage III/IV | 46 |
|
